Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
May 09 2019 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology
company focused on discovering and developing novel biologic
therapeutics to treat rare immune-mediated diseases, today
announced that Craig Wheeler, President and CEO, will present at
the 2019 Bank of America Merrill Lynch Healthcare Conference.
The presentation is scheduled for Thursday, May 16, 2019 at 9:20
a.m. PT (12:20 p.m. ET).
A webcast of the presentation will be available
live on the “Investors” section of the company’s website located at
www.momentapharma.com. A replay of the presentation will be
posted on the Momenta website approximately one hour after the
event.
About MomentaMomenta is a
biotechnology company with a validated innovative scientific
platform focused on discovering and developing novel therapeutics
to treat rare, immune-mediated diseases and advancing its late
stage biosimilar portfolio. The Company is headquartered in
Cambridge, MA.
To learn more about Momenta, please visit
www.momentapharma.com, which does not form a part of this press
release.
Momenta’s logo, trademarks, and service marks
are the property of Momenta Pharmaceuticals, Inc. All other trade
names, trademarks, or service marks are property of their
respective owners.
Forward-Looking
Statement Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements about the use
efficacy, safety, tolerability, convenience and commercial
potential of our product candidates, including their potential as
best-in-class agents. Forward-looking statements may be identified
by words such as "believe," "continue," “plan to”, "potential,"
"will," and other similar words or expressions, or the negative of
these words or similar words or expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors, including the risk of the unpredictable nature
of early stage development efforts for our product candidates;
safety, efficacy or tolerability problems with our product
candidates; unexpected adverse clinical trial results; and those
referred to under the section "Risk Factors" in the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2019
filed with the Securities and Exchange Commission, as well as other
documents that may be filed by the Company from time to time with
the Securities and Exchange Commission. As a result of such risks,
uncertainties and factors, the Company's actual results may differ
materially from any future results, performance or achievements
discussed in or implied by the forward-looking statements contained
herein. The Company is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: Patty Eisenhaur Momenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024